GAITHERSBURG, Md. , April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose

Metered Multidose Device Allows for Convenient and Cost-effective Vaccination GAITHERSBURG, Md. , March 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide leader in nasal spray

New Findings from Ongoing Collaborations with University of Alabama at Birmingham  and Saint Louis University Studies Show Complete Protection Against Lethal Challenge  and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months GAITHERSBURG,

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Md. and BASEL, Switzerland , March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today

GAITHERSBURG, Md. , March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference , being held Mar 9-10,

Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and in a preclinical study induced local nasal mucosal immunity believed to be critical for preventing

Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants  of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through the Phase 1 Clinical Trial Solidly Capitalized to Advance Pipeline Candidates with $216 Million in  Cash and

GAITHERSBURG, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25 th , 2021. Altimmune management will host a conference call for

Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week GAITHERSBURG, Md. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S.